相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
Queenie Hoi-Wing Wong et al.
MODERN PATHOLOGY (2021)
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification
Giulia Berzero et al.
NEURO-ONCOLOGY (2021)
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
Kaspar Draaisma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Daniel J. Brat et al.
ACTA NEUROPATHOLOGICA (2020)
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations
Rui Ryan Yang et al.
BRAIN PATHOLOGY (2020)
Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas
Andrew L. Lin et al.
BRAIN PATHOLOGY (2020)
Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition
Gourish Monday et al.
ACTA NEUROPATHOLOGICA (2020)
Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of dual-genotype IDH-mutant infiltrating gliomas
Cinthya J. Zepeda-Mendoza et al.
ACTA NEUROPATHOLOGICA (2020)
Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation
David Castel et al.
ACTA NEUROPATHOLOGICA (2020)
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
Scott Ryall et al.
CANCER CELL (2020)
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Matthew Clarke et al.
CANCER DISCOVERY (2020)
Infratentorial IDH-mutant astrocytoma is a distinct subtype
Rouzbeh Banan et al.
ACTA NEUROPATHOLOGICA (2020)
A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas
Nayuta Higa et al.
CANCER SCIENCE (2020)
MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Shinji Yamashita et al.
JOURNAL OF NEUROSURGERY (2019)
Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry
Minju Lee et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2019)
Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia
Fausto J. Rodriguez et al.
BRAIN PATHOLOGY (2019)
Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
Karisa C. Schreck et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates
David N. Louis et al.
BRAIN PATHOLOGY (2019)
Detection and Correlation of Single and Concomitant TP53, PTEN, and CDKN2A Alterations in Gliomas
Igor Andrade Pessoa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
Rajarsi Mandal et al.
SCIENCE (2019)
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
Philip Jonsson et al.
CLINICAL CANCER RESEARCH (2019)
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas
Romain Appay et al.
NEURO-ONCOLOGY (2019)
Total copy number variation as a prognostic factor in adult astrocytoma subtypes
Kanish Mirchia et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation
Cheila Brito et al.
BMC CANCER (2019)
Longitudinal molecular trajectories of diffuse glioma in adults
Floris P. Barthel et al.
NATURE (2019)
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Ana S. Guerreiro Stucklin et al.
NATURE COMMUNICATIONS (2019)
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials
Monika E. Hegi et al.
CLINICAL CANCER RESEARCH (2019)
ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features
Adriana Olar et al.
CLINICAL NEUROPATHOLOGY (2019)
Integrated molecular characterization of IDH-mutant glioblastomas
A. Korshunov et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2019)
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation
David W. Ellison et al.
ACTA NEUROPATHOLOGICA (2019)
A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up
R. T. Rajeswarie et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro et al.
NEURO-ONCOLOGY (2018)
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2018)
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
Mitsuaki Shirahata et al.
ACTA NEUROPATHOLOGICA (2018)
Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach
MichaÅ BieÅkowski et al.
CLINICAL NEUROPATHOLOGY (2018)
DNA methylation-based classification of central nervous system tumours
David Capper et al.
NATURE (2018)
Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas
Hyun Sik Kim et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma
Damian Stichel et al.
ACTA NEUROPATHOLOGICA (2018)
cIMPACT-NOW update 3: recommended diagnostic criteria for Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV
Daniel J. Brat et al.
ACTA NEUROPATHOLOGICA (2018)
Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes
Tina Huang et al.
Oncotarget (2018)
BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity
Nozomi Nakajima et al.
BRAIN PATHOLOGY (2018)
Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis
Andrey Korshunov et al.
BRAIN PATHOLOGY (2018)
Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts
Alberto Broniscer et al.
BRAIN PATHOLOGY (2018)
Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel
Angela Zacher et al.
BRAIN PATHOLOGY (2017)
Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status
Marta Mellai et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors
Jamal H. Carter et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients
Guoqiang Yuan et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations
John C. DeWitt et al.
NEURO-ONCOLOGY (2017)
Adult IDH wild-type lower-grade gliomas should be further stratified
Abudumijit Aibaidula et al.
NEURO-ONCOLOGY (2017)
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James R. Perry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications
Alba A. Brandes et al.
ONCOLOGIST (2017)
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas
Leiming Wang et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1
Tali Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
Yujin Lee et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients
Veronique Quillien et al.
CANCER BIOMARKERS (2017)
Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification
Maarten M. J. Wijnenga et al.
ACTA NEUROPATHOLOGICA (2017)
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
Alan Mackay et al.
CANCER CELL (2017)
H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers
Andrey Korshunov et al.
ACTA NEUROPATHOLOGICA (2017)
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity
Andrey Korshunov et al.
ACTA NEUROPATHOLOGICA (2016)
Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations
David A. Solomon et al.
BRAIN PATHOLOGY (2016)
MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry
S. Trabelsi et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas
Ekkehard Hewer et al.
HISTOPATHOLOGY (2016)
Integrated genomic characterization of IDH1-mutant glioma malignant progression
Hanwen Bai et al.
NATURE GENETICS (2016)
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial
Hendrikus J. Dubbink et al.
NEURO-ONCOLOGY (2016)
TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas
Ke Gao et al.
ONCOTARGET (2016)
Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology
Ibrahim Qaddoumi et al.
ACTA NEUROPATHOLOGICA (2016)
Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma
Jung-Soo Pyo et al.
BRAIN TUMOR PATHOLOGY (2016)
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism
Lori Ramkissoon et al.
CANCER RESEARCH (2016)
World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages
Natsuki Hattori et al.
CANCER SCIENCE (2016)
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
Michele Ceccarelli et al.
CELL (2016)
Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas
Masako Ikemura et al.
HISTOPATHOLOGY (2016)
Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach
K. S. Rajmohan et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival
Ajay Chaurasia et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2016)
Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing 1p/19q Co-Deletion Analysis of Gliomas
Hendrikus J. Dubbink et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion
Laura Fontana et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2016)
IDH-1R132H mutation status in diffuse glioma patients: implications for classification
Peng-fei Wang et al.
ONCOTARGET (2016)
GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction
Pablo Alonso-Coello et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction
Pablo Alonso-Coello et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ATRX immunostaining predicts IDH and H3F3A status in gliomas
Azadeh Ebrahimi et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2016)
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
Adriana Olar et al.
ACTA NEUROPATHOLOGICA (2015)
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers
Andrey Korshunov et al.
ACTA NEUROPATHOLOGICA (2015)
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes
David Castel et al.
ACTA NEUROPATHOLOGICA (2015)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller et al.
CLINICAL CANCER RESEARCH (2015)
CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II-III) Astrocytomas
Gerald F. Reis et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2015)
Mutational landscape and clonal architecture in grade II and III gliomas
Hiromichi Suzuki et al.
NATURE GENETICS (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Daniel J. Brat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas
Ming-Yang Li et al.
PLOS ONE (2015)
IDH1 mutation detection by droplet digital PCR in glioma
Jing Wang et al.
ONCOTARGET (2015)
Combination genetic signature stratifies lower-grade gliomas better than histological grade
Aden Ka-Yin Chan et al.
ONCOTARGET (2015)
Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true oligoastrocytoma?
Jason T. Huse et al.
ACTA NEUROPATHOLOGICA (2015)
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
David E. Reuss et al.
ACTA NEUROPATHOLOGICA (2015)
Revisiting TP53 Mutations and Immunohistochemistry-A Comparative Study in 157 Diffuse Gliomas
Hirokazu Takami et al.
BRAIN PATHOLOGY (2015)
Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM
Pankaj Pathak et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Aden Ka-Yin Chan et al.
MODERN PATHOLOGY (2015)
MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens
Laura Lattanzio et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2015)
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma
Felix Sahm et al.
ACTA NEUROPATHOLOGICA (2014)
A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas
Sriram Venneti et al.
ACTA NEUROPATHOLOGICA (2014)
Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas
Denise Bechet et al.
ACTA NEUROPATHOLOGICA (2014)
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
M. Labussiere et al.
BRITISH JOURNAL OF CANCER (2014)
TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas
Emeline Gillet et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy
Giuseppe Minniti et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients
Veronique Quillien et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
Marzena Anna Lewandowska et al.
MOLECULAR DIAGNOSIS & THERAPY (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
Gang Wu et al.
NATURE GENETICS (2014)
Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas
Agusti Alentorn et al.
NEURO-ONCOLOGY (2014)
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial
Benedikt Wiestler et al.
NEURO-ONCOLOGY (2014)
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone
Remco J. Molenaar et al.
NEURO-ONCOLOGY (2014)
Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes
Marianne Labussiere et al.
NEUROLOGY (2014)
The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis
An-an Yin et al.
PLOS ONE (2014)
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
Patrick J. Killela et al.
ONCOTARGET (2014)
ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples
Jinquan Cai et al.
ONCOTARGET (2014)
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas
Jane B. Cryan et al.
ONCOTARGET (2014)
Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
J. Polivka et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial
Vincent Peter Collins et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma
Aurelie Catteau et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis
Benedikt Wiestler et al.
ACTA NEUROPATHOLOGICA (2013)
TERT promoter mutations in primary and secondary glioblastomas
Naosuke Nonoguchi et al.
ACTA NEUROPATHOLOGICA (2013)
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Christian Koelsche et al.
ACTA NEUROPATHOLOGICA (2013)
How Molecular Testing Can Help (and Hurt) in the Workup of Gliomas
Kenneth Clark et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Bette Kay Kleinschmidt-DeMasters et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
MGMT Promoter Methylation and Glioblastoma Prognosis: A Systematic Review and Meta-analysis
Yang Chen et al.
ARCHIVES OF MEDICAL RESEARCH (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations
Christian Hartmann et al.
CLINICAL CANCER RESEARCH (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?
Marco Gessi et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution
Sandra H. E. Boots-Sprenger et al.
MODERN PATHOLOGY (2013)
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome
Shadi Lalezari et al.
NEURO-ONCOLOGY (2013)
CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry
Suvendu Purkait et al.
NEUROPATHOLOGY (2013)
1p/19q testing has no significance in the workup of glioblastomas
K. H. Clark et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2013)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
Lori A. Ramkissoon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Frequency of TERT promoter mutations in human cancers
Joao Vinagre et al.
NATURE COMMUNICATIONS (2013)
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
Dong-Anh Khuong-Quang et al.
ACTA NEUROPATHOLOGICA (2012)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
Pierre Bady et al.
ACTA NEUROPATHOLOGICA (2012)
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide
Emmanuele Lechapt-Zalcman et al.
CANCER (2012)
Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients
Veronique Quillien et al.
CANCER (2012)
Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma
Dominik Sturm et al.
CANCER CELL (2012)
Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor Heterogeneity
Suzanne E. Little et al.
CANCER RESEARCH (2012)
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients
Akitake Mukasa et al.
CANCER SCIENCE (2012)
IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
Daniel Gorovets et al.
CLINICAL CANCER RESEARCH (2012)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Guido Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations
Shani Mulholland et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas
Ichiyo Shibahara et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2012)
Analysis of Isocitrate Dehydrogenase 1 Mutation in 97 Patients with Glioma
You-Xin Zhou et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2012)
Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system
Dominique Figarella-Branger et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas
Rezvan Ahmadi et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas
Tareq A. Juratli et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors
Marta Mellai et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Jeremy Schwartzentruber et al.
NATURE (2012)
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
Gang Wu et al.
NATURE GENETICS (2012)
Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma
Arne Christians et al.
PLOS ONE (2012)
Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event
Ulrike Lass et al.
PLOS ONE (2012)
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology
David Capper et al.
ACTA NEUROPATHOLOGICA (2011)
A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts
Deborah S. Malley et al.
ACTA NEUROPATHOLOGICA (2011)
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
Genevieve Schindler et al.
ACTA NEUROPATHOLOGICA (2011)
IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group
Ian F. Pollack et al.
CHILDS NERVOUS SYSTEM (2011)
IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature
Prerana Jha et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2011)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors
Marta Mellai et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens
Matthias Preusser et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2011)
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Brock C. Christensen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas
Song-Tao Qi et al.
ONCOLOGY REPORTS (2011)
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Christopher M. Heaphy et al.
SCIENCE (2011)
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing
Joerg Felsberg et al.
ACTA NEUROPATHOLOGICA (2010)
Molecular diagnostics of gliomas: the clinical perspective
Ghazaleh Tabatabai et al.
ACTA NEUROPATHOLOGICA (2010)
MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas
Ruth G. Tatevossian et al.
ACTA NEUROPATHOLOGICA (2010)
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2010)
Segregation of Non-p.R132H Mutations in IDH1 in Distinct Molecular Subtypes of Glioma
Lonneke A. M. Gravendeel et al.
HUMAN MUTATION (2010)
The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma
Bomi Kim et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2010)
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
M. Labussiere et al.
NEUROLOGY (2010)
Worse Outcome in Primary Glioblastoma Multiforme With Concurrent Epidermal Growth Factor Receptor and p53 Alteration
Yolanda Ruano et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Determination of EGFR Status in Gliomas Usefulness of Immunohistochemistry and Fluorescent In Situ Hybridization
Angelique Guillaudeau et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: Observer variability and lack of association with patient survival impede its use as clinical biomarker
Matthias Preusser et al.
BRAIN PATHOLOGY (2008)
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma
Ilse Vlassenbroeck et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas
Mingqi Qu et al.
ACTA NEUROPATHOLOGICA (2007)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
